Journal
ANNALS OF NEUROLOGY
Volume 68, Issue 3, Pages 392-395Publisher
WILEY-LISS
DOI: 10.1002/ana.22074
Keywords
-
Categories
Funding
- Merck-Serono
- Novartis
- Actelion
- Biogen Idec
- Bayer Schering
- Teva
- GlaxoSmithKline
- UCB
- Roche
- Antisense Therapeutics
- Bayer Schering Pharma
Ask authors/readers for more resources
It has been suggested that natalizumab-associated progressive multifocal leukoencephalopathy may be prevented by structured interruptions of treatment. Evidence supporting such a drug holiday is not yet available. Here we present initial observations in 10 multiple sclerosis patients who were stringently monitored up to 6 months after discontinuation of the infusions. Cumulatively, a combination of clinical relapse and new and/or enhanced lesions on magnetic resonance imaging had occurred in 7 of 10 patients. Although numbers are small, our data suggest that in patients who were switched to natalizumab because of disease activity despite first-line treatment, a natalizumab drug holiday without reinstatement of alternate disease-modifying therapy is poorly tolerated. ANN NEUROL 2010;68:392-395
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available